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Background: Despite of increasing prevalence of bacterial resistance to antibiotics and possible adverse drug
reactions (ADRs), uncomplicated lower urinary tract infections (uUTIs) are usually treated with antibiotics.
Canephron® N, a herbal medicinal product, was now investigated for safety and efficacy in women suffering
from uUTI.
Methods: In an open-label, non-randomized, multicentre clinical trial 125 Caucasian female patients suffering
from uUTI with a sum score of at least 6 for the symptoms dysuria, frequency and urgency (each rated 0–4) were
enrolled. Patients were treated with 3x2 tablets Canephron® N for seven days. Symptom assessment was performed
by the patient on a daily basis and by the investigator at Day 0, Day 7, Day 37. Primary endpoint was the incidence
of ADRs during the treatment. Secondary endpoints were clinical cure (none of the main symptoms scored as
worse than mild (“1”)) on Day 7, severity of uUTI symptoms on Day 7 and Day 37, patients requiring antibiotic
treatment until Day 7, duration of uUTI symptoms and patients with early recurrence. Changes in safety data
(dipstick analysis of urine; analysis of blood and urine in a central laboratory) were analysed descriptively. Further
post hoc analyses were performed.
Results: None of 19 adverse events within the study period was considered as drug-related or serious. The
responder rate was 71.2 % on Day 7 and 85.6 % on Day 37 (FAS, N = 125) with a significant improvement of all
symptoms (all: p < 0.001). Only 2.4 % of patients required antibiotics during the treatment period and none of
the patients met the definition of recurrence until Day 37. The mean changes of the main symptoms on Day 7
and Day 37 compared to Day 0 were: −1.9/-2.3 (dysuria); −1.8/-2.4 (frequency); −1.6/-1.9 (urgency). Symptomatic
improvement was accompanied by decreased nitrite, leukocytes as well as erythrocyte levels from Day 0 to Day 7
and Day 37.
Conclusions: This trial emphasises the safe usage and efficacious opportunity of a non-antibiotic therapy approach
with Canephron® N and fully justifies a large-scale controlled clinical trial.
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After infections of the respiratory tract, urinary tract infec-
tions (UTIs) represent the second most frequent bacterial
infections in women. Most of them (80 %) are uncompli-
cated UTIs (uUTIs) [1, 2]. Common uUTI symptoms are
frequency, urgency, dysuria and suprapubic pain, while low
back/flank complaints, loin pain and fever are often consid-
ered as symptoms of pyelonephritis. The acute uUTI is
characterized by absence of structural and functional ab-
normalities of the urinary tract, whereas relevant kidney
diseases and relevant comorbidities increase the risk for
complicated UTI with a more serious outcome [3]. Most
frequent uropathogens are Escherichia coli (E. coli) followed
by Staphylococci, Enterococci and Enterobacteriaceae such
as Klebsiella subspecies (spp.). Acute uUTIs are usually
treated by general practitioners in primary health care.
Studies of UTIs usually focus on bacteriology, drug resist-
ance and bacteriological outcome of antibiotic treatment al-
though newer guidelines for treatment of UTIs require
eradication of both bacteriuria and symptoms [4, 5]. In
order to prevent unnecessary consumption, antibiotics
should be prescribed for symptomatic bacteriuria and not
for symptoms only [6, 7].
It is known that many women with uUTI do not seek
medical help immediately, but try to wait or treat them-
selves with home remedies [8]. The natural course of
untreated uUTIs has previously been described in several
studies with a resolution rate of up to 50 % after three days
[1, 3, 6, 7]. In a well-designed trial, Ferry et al. observed a
spontaneous 28 % cure rate of symptoms in the first week,
followed by 37 % after 5–7 weeks [7]. In a pilot trial,
Bleidorn et al. reported on the non-inferiority of ibuprofen
versus ciprofloxacin based on symptomatic outcome on
Day 4, however, one third of patients of the ibuprofen
group relapsed within the first week [6]. Thus, there is only
little evidence for the natural course of untreated uUTIs or
for proven alternative treatment options. Facing increasing
antibiotic resistances, efforts to either optimize appropriate
anti-microbial use or to develop alternative treatment gain
in importance.
Canephron® N, a herbal medicinal product containing
centaury herb, lovage root and rosemary leaves was devel-
oped for irrigation therapy of acute and chronic infections
of the urinary tract and for the prevention of kidney gravel
[9]. The individual components have been characterized to
exhibit spasmolytic, diuretic, anti-inflammatory and anti-
microbial properties [9]. Centaury herb, containing xan-
thones, has antibacterial and anticholinergic effects [10, 11]
and is traditionally used as “supportive for expulsion of
kidney stones” as well as for diuresis [12–14]. Lovage root
with its furanocoumarines is proven to have spasmolytic
and diuretic effects [15, 16] and is proven for irrigation
therapy of lower urinary tract inflammation [15]. Rosemary
leaves, containing diterpenes, polyphenols and phenols withantioxidative, antibacterial, antiviral, anti-inflammatory,
spasmolytic and anticonvulsant effects [17, 18], are sup-
portive for renal excretion and diuresis [4, 14, 19, 20]. In a
systematic review of 17 clinical studies with 3115 patients,
Canephron® N was shown to be effective in the treatment
and prophylaxis of UTI compared with standard therapy,
both in adults and children accompanied by a reduced
number of relapses [21]. Only one adverse event (AE) was
reported (skin rash). It was concluded that Canephron®
N has a positive impact on infectious and inflammatory
processes within the urinary tract. However, because
some of these studies were not well-designed, their in-
ternal and external validity remains unclear [21].
The objective of this trial was to assess safety and thera-
peutic impact of a non-antibiotic therapy approach, treat-
ment with Canephron® N, in the management of uUTIs.
Methods
The present open-label, non-controlled, multicentre,
interventional clinical trial was conducted in nine
Ukrainian sites between October 2011 and June 2012.
The study consisted of a seven-day treatment period
of Canephron® N and a follow-up period until Day 37.
Three visits were planned on Day 0 (Visit 1: Enrolment,
start of treatment), Day 7 ± 1 day (Visit 2: End of treat-
ment) and Day 37 ± 1 day (Visit 3: End of study). In case
the patients experienced persisting or worsening of
symptoms, antibiotic therapy was allowed, stopping
Canephron® N application (Fig. 1).
The severity of uUTI symptoms was assessed by the pa-
tient on a daily basis in the diary as well as by the investiga-
tor at each study visit (Fig. 1) in the CRF. The following
uUTI symptoms were rated on a 5-point scale (Table 1):
dysuria, frequency, urgency, acute development of incontin-
ence or worsening of incontinence, nocturia, pain or dis-
comfort in lower abdomen or pelvic areas and increased
body temperature (fever). For clinical outcome (clinical
cure, improvement, failure) only the three main symp-
toms, dysuria, frequency, urgency, were assessed. The
symptom score was developed on the basis of several
guidelines for urological diseases [6, 22–24].
Exploratory variables were haematology and clinical
blood chemistry (visit 1 and 2) as well as midstream urine
analysis (specific gravity, pH, leucocytes, erythrocytes, ni-
trite, glucose, protein, ketone, urobilinogen, bilirubin, blood;
Combur 10 Dipstick Test, Roche Germany) and standard
microbiological culture of a central laboratory (visit 1, 2
and 3).
In total 125 patients were enrolled into the trial (full
analysis set (FAS)). Of these, 105 patients were distrib-
uted to the per protocol set (PPS, Fig. 2).
The study was performed in accordance with the
Declaration of Helsinki, International Conference on
Harmonization and Good Clinical Practice (ICH-GCP)
Fig. 1 Study design overview (uUTI = uncomplicated urinary tract infection)
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standardize the test results.Main inclusion criteria, patient characteristics
Signed informed consent; female outpatients aging
from 18–65 years; patients suffering from acute symp-
toms of uUTI (cystitis) at screening exhibiting a total
sum score of at least 6 for the following symptoms: dys-
uria (pain during micturition), frequency (pollakisuria),
urgency (Table 1); development of symptoms within a
maximum of six days before screening; non-lactatingTable 1 Rating scale for assessment of uncomplicated urinary tract
infection (uUTI) symptoms by patient and investigator.
Score Rating of uUTI symptoms
0 absent
1 mild (no influence on daily activities or sleep)
2 moderate (minor influence on daily activities or sleep)
3 severe (major influence on daily activities or sleep)
4 very severe (impossible to carry out daily activities or to sleep)
Assessed uUTI symptoms are dysuria, frequency, urgency, acute
development of incontinence or worsening of incontinence, nocturia,
pain or discomfort in lower abdomen or pelvic areas, increased body
temperature. Assessed uUTI symptoms for inclusion and clinical outcome
(clinical cure, improvement, clinical failure) are only the main symptoms,
dysuria, frequency and urgencyfemale patients or patients with a negative pregnancy
test at screening willing to use effective contraception
methods.Main exclusion criteria
Exhibiting any signs evoking complicated UTI, pyelo-
nephritis (fever ≥ 38 °C, back pain, chills and shivers)
and/or concomitant vulvovaginitis; conditions leading
to complicated infections (renal diseases, urinary tract
abnormalities, past urinary surgery, urine catheterization,
etc.); chronic infection of the urinary tract requiring an
intravenous pyelogram, ultrasound or cystoscopy; current
signs of severe, progressive or uncontrolled life-threatening
systemic disease, that is endocrine, pulmonary, cardiac,
neurological, cerebral, renal, hepatic, haematological or
gastrointestinal disease; other acute infection requiring
antibiotic treatment; patients with proven UTI within
four weeks before enrolment; antibiotic, immunosup-
pressive or immune-stimulant therapy within four
weeks prior to study entry.
Further concomitant therapies were prohibited: Rosmar-
ini folium, Levistici radix and Centauri herba supplements
other than the study product, anti-inflammatorydrugs,
spasmolytics, herbal drugs or supplements, Cranberry juice,
kidney or bladder teas. Paracetamol as primary analgetic
drug was allowed for relieving pain.
Fig. 2 Number of screened patients in different statistical analysis sets. This figure shows the number of patients screened, completing Visit 2,
completing Visit 3 and included in the safety set (SA), full analysis set (FAS) and per protocol set (PPS)
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of administration
The IMP, Canephron® N coated tablets, was administrated
orally for seven consecutive days, two tablets three times a
day (as specified in the Ukrainian summary of product
characteristics (SmPC)).
Definitions
Based on the symptom assessments a sum score (ranging
from 0 to 12) was calculated considering only the main
symptoms dysuria, frequency and urgency. A responder
(clinical cure) was defined as a patient with none of these
three symptoms assessed as “worse than mild” with a max-
imum sum score of 3. The number of days from start of
treatment until the respective symptom was assessed as
“not worse than mild” was defined as the duration of each
symptom. For early recurrence the following criteria had to
be fulfilled: patient considered to be a responder on Day 7,
worsening of symptoms in the follow-up period (sum
score ≥ 6) and a microbiological test result indicating ≥ 104
colony forming units (CFU/ml). For calculation of re-
sponder (clinical cure) rates and early recurrences, investi-
gators’ assessments were used whereas the duration of
symptoms was analysed based on patient diaries’ data.Table 2 Categories of patients’ outcome based on symptom assess
Definition according to study protocol
Responder None of the symptoms dysuria, frequency and urgency
worse than mild (i.e. sum score ≤3)
Non-Responder At least one of the symptoms dysuria, frequency and
urgency worse than mildFor more detailed information, a post-hoc analysis was
performed dividing the non-responders into two sub-
categories, namely patients whose symptoms improved
(but were not cured) and patients with clinical failure of
the treatment. In this classification responders were
denominated as patients who were clinically cured.
Patients were considered as improved if the sum score < 6
and if they do not fulfil the criterion for clinical cure. In
case of clinical failure of the treatment, the sum score of
the patient was ≥ 6 (Table 2). Due to the fact that the
methods of the central laboratory for determining the bac-
terial count were sensitive enough to consistently pick up
even lower bacterial counts as initially assumed during gen-
erating the study protocol, it was decided to change the cri-
terion for significant bacteriuria from 104 CFU/ml to the
more sensitive threshold of 103 CFU/ml.
Study endpoints
Primary endpoint was the incidence of adverse drug reac-
tions (ADRs) during the seven-day treatment of uUTI
symptoms with Canephron® N. An ADR was defined as
any untoward medical occurrence which started during
treatment with Canephron® N and which has a causal rela-
tionship to this treatment. AEs were assessed either byment by investigator
Definition for post-hoc analysis
Clinical cure None of the symptoms dysuria, frequency and urgency
worse than mild (i.e. sum score ≤3)
Improved Sum score < 6 and criterion for clinical cure not fulfilled
Clinical Failure Sum score≥ 6
Table 3 Reasons for patients being excluded from the per
protocol set (PPS)
Number of patients Reason for exclusion from PPS
1 Non-compliance (<80 %)
2 Missing of relevant lab data
2a Drop out before Day 3
7 Major deviation from visit window
8 Intake of forbidden concomitant therapy
aDropped out due to lost to follow-up and withdrawal of informed consent
Table 4 Change of patient symptom status from Day 7 to Day
37 categorized by age
Day 7 Day 37
N % N %
Total (N = 125) Clinical Cure 89 71.2 107 85.6
Improvement 24 19.2 10 8.0
Clinical Failure 12 9.6 8 6.4
≤45 years (N = 68) Clinical Cure 55 80.9 64 94.1
Improvement 9 13.2 2 2.9
Clinical Failure 4 5.9 2 2.9
>45 years (N = 57) Clinical Cure 34 59.7 43 75.4
Improvement 15 26.3 8 14.0
Clinical Failure 8 14.0 6 10.5
Number (N) and percentage (%) of patients whose symptom status was
assessed as “clinical cure” (sum score* ≤ 3), “improvement” (3 < sum score < 6)
or “clinical failure” (sum score ≥ 6) on Day 7 and Day 37, for all patients and
categorized into women aged ≤ 45 years or > 45 years (full analysis
set, N = 125)
*sum of the three main symptoms (dysuria, frequency and urgency) rated on a
5-point scale (0 – absence, 1 – mild, 2 – moderate, 3 – severe, 4 – very severe)
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self-reporting by the patient or via physical examination
or laboratory tests.
Secondary endpoints were the proportion of responder
(clinical cure) on Day 7, severity of uUTI symptoms on
Day 7 and Day 37, duration of symptoms, proportion of
patients requiring antibiotic treatment until Day 7 and
the proportion of patients with early recurrence.
Statistics
The primary endpoint of the study, the incidence of
ADRs within the seven-day treatment with Canephron®
N, was evaluated descriptively. Statistical hypothesis tests
of the primary as well as secondary endpoints were not
planned; the sample size was discussed with respect to
the accuracy of the expected proportions of ADRs.
Clopper–Pearson confidence limits for the incidence
rate were calculated.
The assessment of symptom severity was based on a
5-point rating scale (Table 1). Data were analysed de-
scriptively. Changes of the severity of uUTI symptoms
from baseline were analysed by the Wilcoxon-rank test.
Results of vital signs measurements, physical examin-
ation and safety laboratory tests were also analysed
descriptively.
The safety set consisted of patients who received at least
one dose of the study medication, whereas the FAS in-
cluded all patients of the safety set who reported at least
one efficacy endpoint. All patients of the FAS without rele-
vant protocol violations participating in the study were dis-
tributed to the PPS.
The following calculations were performed during the
post-hoc analysis: comparison of the patient and investi-
gator sum score in a descriptive manner, followed by a
Kaplan-Meier curve. In case of significant bacteriuria,
the spectrum of uropathogens was analysed. In case of
“unknown bacteriuria” or “no growth” no bacterial
analysis was possible. For post-hoc analysis the FAS was
used.
Ethical considerations
The clinical trial approval was granted by the competent
authorities of the Ukraine and a favourable opinion of
the Central Commission on Ethics Questions of the
Ministry of Health of Ukraine, the relevant independent
ethics committee, was given prior to the start of the clin-
ical trial. Written informed consent was obtained from
all patients prior to enrolment.
Results
In total, 125 Caucasian women with a mean age of 43.8
years diagnosed with uUTI were enrolled in this open-
label, non-randomized, multicentre interventional study at
nine Ukrainian sites. Eighty-three patients (66.4 %) had anacute uUTI, whereas 42 patients (33.6 %) suffered from an
acute episode of a recurrent infection. The patients demon-
strated excellent compliance (mean 101.8 %). Only 3 out of
122 patients who completed the treatment phase were out
of the accepted compliance range between 80 and 120 % of
the number of tablets to be taken. Twenty patients were
excluded from PPS due to major protocol violations result-
ing in 105 patients within the PPS (Table 3). No patient
dropped out due to switching to antibiotics before Day 3.
Canephron® N was safe and well tolerated. In total 19
AEs, but no serious adverse event (SAE), were reported.
Eleven (8.8 %) of 125 patients experienced at least
one AE, most frequently reporting headache (4.0 %),
followed by abdominal distension (1.6 %). None of the
AEs was considered as drug-related. Thus, the primary
endpoint of the study, the incidence of ADRs within the
seven-day treatment with Canephron® N was 0 % with a
95 % Clopper-Pearson Confidence Interval (CI) between
0.0 and 2.9 % in the safety set.
At the end of the seven-day treatment period, 71.2 % of
patients of the FAS (Table 4) and 70.8% of the PPS met the
definition of clinical cure. The clinical cure rates on Day 37
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ical cure rate was higher in younger women (≤45 years;
cure rate of 80.9 % on Day 7 and 94.1 % on Day 37 respect-
ively) than in women over the age of 45 years (cure rate of
59.7 % on Day 7 and 75.4 % on Day 37 respectively) (FAS;
Table 4). On Day 7, the average improvement (mean
change from baseline, FAS) in the sum score of dysuria, fre-
quency and urgency was −5.4 on Day 7 and −6.6 on Day 37
compared to a mean baseline score of 7.3 (Fig. 3). The
mean changes of the individual symptoms on Day 7/37Fig. 3 Comparison between uUTI sumscore assessed by patients and inves
and urgency; uUTI Sumscore was assessed on Day 0, Day 7 and Day 37 (fu(FAS) compared to Day 0 were: −1.9/-2.3 (dysuria); −
1.8/-2.4 (frequency); −1.6/-1.9 (urgency); −0.4/-0.5 (incon-
tinence); −0.8/-1.1 (nocturia) and −1.0/-1.2 (pain). All
changes from baseline were statistically significant
(p < 0.001). There were only minor differences be-
tween the symptom ratings by the investigators and
by the patients (Fig. 3). The Kaplan-Meier plot illus-
trated in Fig. 4 depicts the number of responders
(symptoms absent versus symptoms not worse than mild)
within the study period demonstrating a fast relieving oftigators. The uUTI Sumscore includes the symptoms dysuria, frequency
ll analysis set, N = 125)
Fig. 4 Kaplan-Meier curve visualizing the proportion of responders at each study day. Responder defined as symptoms dysuria, frequency and
urgency not worse than mild (blue line) or absent (green line) (full analysis set, N = 125)
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uria, frequency, urgency worse than mild within the first
days of treatment (FAS).
The duration of symptoms was on average 5.1 days
(frequency), 3.5 days (dysuria), 2.9 days (urgency), 2.4
days (nocturia), 1.7 days (pain) and 0.9 days (incontin-
ence). The number of non-responders, i.e. the number
of improved patients and patients with clinical failure
(Table 2), decreased within the seven-day treatment
period and up to Day 37 in favour of the proportion of
clinical cured patients (Table 4; FAS).An increased body temperature was not observed in
any patient on Day 7 or Day 37. Three of 125 patients
required antibiotics within the seven-day treatment
period. After Day 7 none of the patients met the defin-
ition of recurrence. No clinically relevant trend was ob-
served in the laboratory tests (haematology and clinical
chemistry), vital signs and physical examinations. None
of the patients finished the trial taking antibiotics.
There was a clear reduction in the number of patients
exhibiting positive results in particular of erythrocytes
(RBC), leucocytes (WBC) and nitrite in urinalysis. WBC
Table 6 Changes in patients bacteriuria spectrum
Day 0 Day 7 Day 37
N % N % N %
Patients 125 100 122 100 121 100
Patients with significant bacteriuria 65 52.0 65 53.3 61 50.4
Total isolates 87 100 83 100 79 100
E.coli 35 40.2 36 43.4 31 39.2
Klebsiella spp. 4 4.6 4 4.8 4 5.1
Proteus spp. 3 3.4 2 2.4 5 6.3
Other Enterobacteriaceae 1 1.1 3 3.6 2 2.5
Enterococci 34 39.1 28 33.7 32 40.5
Staphylococci 4 4.6 4 4.8 3 3.8
Streptococci 1 1.1 2 2.4 0 0.0
Other Gram positives 5 5.7 4 4.8 2 2.5
Number (N) and percentage (%) of patients with significant bacteriuria (≥ 103
colony forming units (CFU)/ml) on Day 0, Day 7 and Day 37 and the respective
spectrum of uropathogens
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and 77.6 % (Day 37). On Day 37, 93.6 % of the patients
were nitrite-negative and 80.0 % RBC-negative (dipstick
tests, Table 5, FAS). Of 65 patients suffering from signifi-
cant bacteriuria on Day 0, only 40 still exhibited ≥103
CFU/ml up to Day 37. However, of 50 patients without sig-
nificant bacteriuria, 14 developed a significant bacteriuria
up to Day 37. Of 10 patients with unknown bacteriuria on
Day 0, 7 patients showed a significant bacteriuria on Day
37 (Fig. 5). Thus, the total number of patients with signifi-
cant bacteriuria and the bacterial spectrum remained
almost unchanged on Day 0, Day 7, and Day 37 with E. coli
as the most frequent uropathogen followed by Enterococci
(Table 6). The clinical cure rate of patients exhibiting <103
CFU/ml on Day 0 was 88.0 % on Day 7 and 98.0 % on Day
37, whereas the corresponding cure rates in patients exhi-
biting ≥103 CFU/ml on Day 0 were 62.9 % on Day 7 and
77.4 % on Day 37, respectively, and thus significantly lower
(p < 0.005). In the group <103 CFU/ml the number of pa-
tients with clinical failure was 1 (2.0 %) on Day 7 and 0 (0.0
%) on Day 37, whereas the number of patients with clinical
failure in the group ≥ 103 CFU/ml was 7 (11.3 %) on Day 7
and 4 (6.5 %) on Day 37 (Table 7).
Discussion
During one year, 11 % of women suffer from at least one
UTI episode and more than half of all women have one or
more infections during their lifetime [25]. Each year, in
the United States, acute cystitis is responsible for 3.6 mil-
lion office visits by women 18–75 years old, accounting
for direct costs of $ 1.6 billion [25]. Most of acute lower
UTIs (acute bacterial cystitis) are uncomplicated. They
were not associated with signs or symptoms of upper UTIs
(fever, chills, flank pain) or with other characteristics sug-
gesting a higher risk of upper or complicated infection (e.g.
diabetes mellitus, pregnancy, immunosuppression, previousTable 5 Changes in Urine Dipstick status from Day 0 to Day7
and Day 37
Urine Dipstick Day 0 Day 7 Day 37
N % N % N %
Nitrite Missing 0 0.0 3 2.4 4 3.2
Negative 98 78.4 115 92.0 117 93.6
Positive 27 21.6 7 5.6 4 3.2
RBC Missing 0 0.0 3 2.4 4 3.2
Negative 70 56.0 92 73.6 100 80.0
Positive 55 44.0 30 24.0 21 16.8
WBC Missing 0 0.0 3 2.4 5 4.0
Negative 22 17.6 88 70.4 97 77.6
Positive 103 82.4 34 27.2 23 18.4
Number (N) and percentage (%) of patients with missing, negative or positive
dipstick urine analysis results regarding nitrite, red blood cells (RBC) and white
blood cells (WBC) on Day 0, Day 7 and Day 37 (full analysis set, N = 125)pyelonephritis, structural abnormalities of the urinary tract).
After initial infection many women have sporadic or mul-
tiple recurrences. E. coli causes 70 to 90 % of episodes of
acute uUTI, followed by Staphylococcus saprophyticus,
mainly in young women. Standard treatment is antibiotic
therapy with associated rates of adverse reactions ranging
from 7–40 % for trimethoprim, 0–40 % for nitrofurantoin,
7–21 % for norfloxcacin and 13 % for ciprofloxacin [25].
Duration of antibiotic treatment in this indication is usually
short-term: in a placebo-controlled clinical trial a significant
symptomatic and bacteriological short-term benefit was ob-
served in the therapy of uUTI with three-day treatment
with nitrofurantoin, compared to placebo. After a follow-up
period of two weeks, no statistically significant differences
were found [21]. In addition, antibiotic use may harm
patients suffering from asymptomatic bacteriuria. In the
study of Cai et al. [26] it was concluded to be beneficial not
to treat younger women suffering from asymptomatic
bacteriuria with antibiotics due to a possible protective ef-
fect of colonizing bacteria. Solely symptomatic treatment of
acute uUTI also seems to be an option. Bleidorn et al. re-
ported similar results with ibuprofen versus ciprofloxacin
based on symptomatic outcome in a pilot trial; however,
one third of patients in the ibuprofen group relapsed within
the first week [5].
Therefore, alternatives to antibiotic treatment are war-
ranted. Cranberry, long advocated for prevention of
acute cystitis, contains proanthocyanidines inhibiting the
attachment of pathogens to uroepithelium [27]. 200–500
mg cranberry juice or concentrate tablets reduce the risk
of symptomatic recurrences by 12–20 %, but are not
applicable for treatment of uUTIs [28].
With regard to the current state of uUTI treatment,
the study was designed to evaluate the safety profile of
Fig. 5 Changes in bacteriuria status of patients throughout the clincical trial. Number of patients with significant, non significant and unknown
bacteriuria on Day 0, Day 7 and Day 37 respectively and the changes in bacteriuria status throughout the clinical trial (full analysis set, N = 125). In
case of “unknown bacteriuria” or “no growth” no bacterial analysis was possible
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therapy in the treatment of uUTI. The threshold for signifi-
cant bacteriuria varies between 103 and 105 CFU/ml de-
pending on uropathogens, gender and type of urine sample
[7], therefore the selected thresholds of 104 CFU/ml and
103 CFU/ml for this study were in an acceptable range. The
inclusion as well as exclusion criteria clearly fitted theTable 7 Changes of patient symptom status from Day 7 to Day
37 categorized by status of significant bacteriuria
Day 7 Day 37
N % N %
Total (N = 125a) Clinical cure 89 73.0 107 88.4
Improvement 24 19.7 10 8.2
Clinical failure 9 7.3 4 3.3
< 103/ml (N = 50) Clinical cure 44 88.0b 49 98.0b
Improvement 5 10.0 1 2.0
Clinical failure 1 2.0 0 0.0
≥ 103/ml (N = 62) Clinical cure 39 62.9b 48 77.4b
Improvement 16 25.8 9 14.5
Clinical failure 7 11.3 4 6.5
Unknown (N = 10) Clinical cure 6 60.0 10 100.0
Improvement 3 30.0 0 0.0
Clinical failure 1 10.0 0 0.0
Number (N) and percentage (%) of patients whose symptom status was
assessed as “Clinical cure”, “Improvement” or “Clinical failure” on Day 7 and
Day 37, for all patients and categorized into subgroups with (≥ 103 colony
forming units (CFU)/ml) or without (< 103 CFU/ml) significant bacteriuria (full
analysis set, N = 125)
alost for follow up: 3 patients on Day 7 and 4 patients on Day 37
bdifference between patients with and without significant bacteriuria is
statistically significant (chi2 test; p < 0.005) on Day 7 and on Day 37intended indication which was demonstrated by only 2.4 %
of patients receiving antibiotics.
In this study a resolution rate of 71.2 % after seven-day
treatment and 85.6 % after 37 days (FAS, N = 125) was
achieved under Canephron® N treatment, which was much
more effective than reported spontaneous resolution
[6–8, 21 – 26]. This hints at the efficacy of Canephron®
N treatment. A three-day treatment with nitrofurantoin, ex-
hibited no significant symptomatic difference to untreated
patients after 14 days [21]. In contrast the symptomatic as
well as anti-inflammatory effect is extended up to four
weeks after the end of treatment with Canephron® N on
Day 7 (Fig. 4, Tables 4 and 5).
In a recent meta-analysis of 464 studies of uUTI in
women, frequency and dysuria had a positive correlation
with bacteriuria [29], supporting the observation of symp-
tomatic as well as inflammatory resolution under treatment
with Canephron® N in this study. On the other hand,
asymptomatic bacteriuria does not necessarily need anti-
biotic therapy even in patients suffering from recurrent
cystitis [3, 26].
During UTI, microorganism adhering to the bladder
urothelium cause inflammatory reactions, the bladder gets
hyperactive and patients suffer from increased micturition
frequency and pain. Canephron® N possesses relevant anti-
adhesive and anti-inflammatory activity, possibly modulat-
ing the overactive bladder function, easing bladder func-
tions and preventing adhesion of E. coli, as demonstrated in
several in vitro and in vivo experiments [30, 31]. The bac-
terial spectrum in patients suffering from significant bac-
teriuria did not change significantly during the treatment as
well as observation period in this study (Table 6), indicating
Ivanov et al. Clinical Phytoscience  (2015) 1:7 Page 10 of 11no direct anti-microbial effect of the drug, possibly support-
ing the concept of an immunological adaption process be-
tween uroepithelium and adhering microorganism. The fast
symptomatic resolution of uUTI under Canephron® N
treatment supports the assumption that the multiple phar-
macodynamic targets of Canephron® N are suitable for the
treatment of uUTI.Conclusions
Canephron® N was safe and well tolerated, no ADRs or
SAEs were reported. The responder rate was 71.2 % on Day
7 and 85.6 % on Day 37 (FAS, N = 125). A significant im-
provement was observed for the sum score as well as for all
single symptoms on Day 7 and Day 37. Only 2.4 % of pa-
tients required antibiotics during the seven-day treatment
period and none of the patients suffered from a recurrence
until Day 37 after assessed as clinical cure on Day 7. The
resolution of symptoms continued four weeks after end of
treatment in contrast to many anti-microbial therapies. As
this study was designed to show the safety of Canephron®
N treatment, it is not possible to give a definite statement
about efficacy, but the fast symptomatic resolution of uUTI
under Canephron® N treatment hints at the efficacy of
Canephron® N that needs to be further investigated.
This trial emphasises the safe usage and potential
opportunity of a non-antibiotic therapy approach with
Canephron® N and fully justifies a large-scale controlled
clinical trial to finally establish the significance of
Canephron® N in the management of acute phases of
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